Actively Recruiting

Phase 2
Age: 5Years - 17Years
All Genders
NCT05039619

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Led by Hoffmann-La Roche · Updated on 2026-05-04

40

Participants Needed

42

Research Sites

422 weeks

Total Duration

On this page

Sponsors

H

Hoffmann-La Roche

Lead Sponsor

G

Genentech, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label safety and PK of obinutuzumab in pediatric participants (PP), aged 5 to \<12 with LN.

CONDITIONS

Official Title

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Who Can Participate

Age: 5Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 12 to less than 18 years at randomization
  • Age 5 to less than 12 years at randomization once recruitment opens for this group
  • Biopsy-confirmed active Class III or IV lupus nephritis within 12 months prior to or during screening
  • Class V lupus nephritis may be present alongside Class III or IV, but isolated Class V is not allowed
  • Diagnosis of systemic lupus erythematosus (SLE) according to SLICC 2012 criteria
  • Significant proteinuria defined as urine protein-to-creatinine ratio above 0.5 from first morning void at screening
  • Received at least one dose of pulse-range IV methylprednisolone or equivalent within 12 months prior to or during screening for current lupus nephritis episode
Not Eligible

You will not qualify if you...

  • Severe, active central nervous system lupus including retinitis, poorly controlled seizures, acute confusion, myelitis, stroke, cerebellar ataxia, or dementia
  • Sclerosis in more than 50% of kidney glomeruli on biopsy
  • Purely chronic Class III(c) or Class IV(c) lupus nephritis without active lesions
  • Presence of rapidly progressive glomerulonephritis
  • Pure Class V lupus nephritis
  • Intolerance or contraindication to study treatments
  • Active infection of any kind (except nail bed fungal infection) or recent major infection requiring hospitalization or IV treatment within 4 weeks prior to screening, or completion of oral anti-infective treatment within 2 weeks prior to randomization
  • History or current primary or secondary immunodeficiency including known HIV or severe immunodeficiency blood disorders
  • History of serious recurrent or chronic infection
  • History or current cancer within past 5 years (except excised basal or squamous cell skin carcinoma)
  • Significant or uncontrolled medical conditions that would prevent study participation
  • Current active alcohol or drug abuse or history of such abuse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 42 locations

1

Loma Linda University health

Loma Linda, California, United States, 92354

Actively Recruiting

2

UCSF Benioff Childrens Hospital

San Francisco, California, United States, 94158

Actively Recruiting

3

Children's Hospital Colorado, Anchutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

4

Emory Children's Center

Atlanta, Georgia, United States, 30322

Actively Recruiting

5

Indiana University Health University Hospital

Indianapolis, Indiana, United States, 46202

Actively Recruiting

6

Louisiana State University

Shreveport, Louisiana, United States, 71103

Actively Recruiting

7

Hackensack University Medical Center

Hackensack, New Jersey, United States, 07601

Actively Recruiting

8

Cohen Children's Medical Center of New York

Queens, New York, United States, 11042

Actively Recruiting

9

Cincinnati Childrens Hospital

Cincinnati, Ohio, United States, 45229

Actively Recruiting

10

Chldren?s Hospital of Philadelphia

Philadelphia, Pennsylvania, United States, 19104

Withdrawn

11

Texas Arthritis Center

El Paso, Texas, United States, 79902

Withdrawn

12

Ser Servicos Especializados Em Reumatologia

Salvador, Estado de Bahia, Brazil, 40150-150

Actively Recruiting

13

Centro de Pesquisa São Lucas

Campinas, São Paulo, Brazil, 13060-904

Actively Recruiting

14

Hospital das Clinicas - FMUSP

São Paulo, São Paulo, Brazil, 05403-000

Actively Recruiting

15

Universidade Federal de Sao Paulo - UNIFES

São Paulo, Brazil, 04024-002

Active, Not Recruiting

16

The Hospital for Sick Children

Toronto, Ontario, Canada, M5G 1X8

Actively Recruiting

17

Hospital Sainte-Justine

Montreal, Quebec, Canada, H3T 1C5

Actively Recruiting

18

CH de Bicêtre

Le Kremlin-Bicêtre, France, 94275

Actively Recruiting

19

Hôpital Robert Debré

Paris, France, 75019

Actively Recruiting

20

Hop Necker Enfants Malades

Paris, France, 75743

Actively Recruiting

21

CHU de Toulouse - Hôpital des Enfants

Toulouse, France, 31000

Actively Recruiting

22

Ospedale Pediatrico Bambino Gesu

Rome, Lazio, Italy, 00165

Actively Recruiting

23

IRCCS G. Gaslini

Genoa, Liguria, Italy, 16148

Actively Recruiting

24

Clinica Pediatrica II De Marchi

Milan, Lombardy, Italy, 20122

Actively Recruiting

25

CREA Hospital Mexico Americano

Guadalajara, Jalisco, Mexico, 44620

Actively Recruiting

26

Clinstile S.A de C.V.

Mexico City, Mexico CITY (federal District), Mexico, 06700

Actively Recruiting

27

Hospital Universitario Dr. Jose Eleuterio Gonzalez

Monterrey, Nuevo León, Mexico, 64460

Actively Recruiting

28

Instituto de Ginecología y Reproducción

Lima, Peru

Active, Not Recruiting

29

Clinica El Golf

San Isidro, Peru, L27 Lima

Active, Not Recruiting

30

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland, 80-294

Actively Recruiting

31

Szpital Specjalistyczny dla Dzieci i Doroslych

Torun, Poland, 87-100

Withdrawn

32

Saint-Petersburg State

St-peterburg, Sankt-Peterburg, Russia, 194100

Withdrawn

33

Red Cross War Memorial Children?s Hospital

Cape Town, South Africa, 7700

Withdrawn

34

Groote Schuur Hospital

Cape Town, South Africa, 7925

Withdrawn

35

Panaroma Medical Center

Panorama, South Africa, 7500

Actively Recruiting

36

Hospital Sant Joan De Deu

Esplugas de Llobregat, Barcelona, Spain, 08950

Actively Recruiting

37

Hospital Ramon y Cajal

Madrid, Spain, 28034

Actively Recruiting

38

Hospital de La Paz

Madrid, Spain, 28046

Actively Recruiting

39

Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica

Valencia, Spain, 46026

Actively Recruiting

40

Royal Hospital For Children

Glasgow, United Kingdom, G51 4TF

Withdrawn

41

Alder Hey Childrens Hospital

Liverpool, United Kingdom, L12 2AP

Actively Recruiting

42

Great Ormond Street Hospital for Children

London, United Kingdom, WC1N 3JH

Actively Recruiting

Loading map...

Research Team

R

Reference Study ID Number: WA42985 https://forpatients.roche.com/

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants | DecenTrialz